Therefore, PPAR-α and its target genes agonists may useful for amelioration of NAFLD through their increased lipid oxidation properties as demonstrated with the well-known PPAR-α activator, saroglitazar [25]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.